Skip to content
2000
image of Recent Advances and Future Directions in 5-Fluorouracil Drug Delivery: A Comprehensive Review

Abstract

Given the multiple challenges associated with the clinical use of 5-fluorouracil (5-FU), including pronounced fluctuations in plasma concentrations, significant interindividual metabolic variability, and frequent systemic adverse reactions, this study systematically examines the advantages and prospects of innovative 5-FU delivery strategies. These strategies aim to overcome its clinical limitations. To this end, molecular engineering approaches, such as Prodrug Technology, cocrystal technology, and conjugate design, are utilised to enhance permeability, solubility, and targeted release. In addition, microenvironmental regulation strategies modulate both systemic and tumor microenvironments, enhancing therapeutic efficacy and potentially reversing drug resistance. Furthermore, multifunctional, stimuli-responsive delivery carriers and devices now enable precise, intelligent drug release. Notably, as drug delivery technologies advance, emerging evidence suggests that single strategies cannot fully address the challenges of 5-FU administration. Therefore, multidimensional synergistic approaches significantly improve 5-FU bioavailability, reduce systemic toxicity, and optimize therapeutic outcomes. Looking forward, integrating multiple strategies within a multidisciplinary framework may offer a valuable paradigm for designing delivery systems for pyrimidine-based antimetabolite drugs.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ctmc/10.2174/0115680266429032251207122337
2026-02-20
2026-02-26

  • From This Site

    /content/journals/ctmc/10.2174/0115680266429032251207122337
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Bray F. Laversanne M. Sung H. Ferlay J. Siegel R.L. Soerjomataram I. Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024 74 3 229 263 10.3322/caac.21834 38572751
    [Google Scholar]
  2. Salmani-Javan E. Farhoudi Sefidan Jadid M. Zarghami N. Recent advances in molecular targeted therapy of lung cancer: Possible application in translation medicine. Iran. J. Basic Med. Sci. 2024 27 2 122 133 38234663
    [Google Scholar]
  3. Kaur R. Bhardwaj A. Gupta S. Cancer treatment therapies: Traditional to modern approaches to combat cancers. Mol. Biol. Rep. 2023 50 11 9663 9676 10.1007/s11033‑023‑08809‑3 37828275
    [Google Scholar]
  4. Zoetemelk M. Ramzy G.M. Rausch M. Nowak-Sliwinska P. Drug-drug interactions of irinotecan, 5-fluorouracil, folinic acid and oxaliplatin and its activity in colorectal carcinoma treatment. Molecules 2020 25 11 2614 10.3390/molecules25112614 32512790
    [Google Scholar]
  5. Chan W.L. Choi C.W. Wong I.Y.H. Tsang T.H.T. Lam A.T.C. Tse R.P.Y. Chan K.K. Wong C. Law B.T.T. Cheung E.E. Chan S.Y. Lam K.O. Kwong D. Law S. Docetaxel, cisplatin, and 5-FU triplet therapy as conversion therapy for locoregionally advanced unresectable esophageal squamous cell carcinoma. Ann. Surg. Oncol. 2023 30 2 861 870 10.1245/s10434‑022‑12694‑8 36307666
    [Google Scholar]
  6. Chavani O. 5-Fluorouracil response prediction and blood level-guided therapy in oncology: Existing evidence fundamentally supports instigation. Ther. Drug Monit. 2020 42 5 660 664 10.1097/FTD.0000000000000788 32649488
    [Google Scholar]
  7. Van Der Heyden S.A. Highley M.S. De Bruijn E.A. Tjaden U.R. Reeuwijk H.J. Van Slooten H. Van Oosterom A.T. Maes R.A. Pharmacokinetics and bioavailability of oral 5′‐deoxy‐5‐fluorouridine in cancer patients. Br. J. Clin. Pharmacol. 1999 47 4 351 356 10.1046/j.1365‑2125.1999.00899.x 10233196
    [Google Scholar]
  8. Ardizzone A. Bulzomì M. De Luca F. Silvestris N. Esposito E. Capra A.P. Dihydropyrimidine dehydrogenase polymorphism c.2194G>A screening is a useful tool for decreasing gastrointestinal and hematological adverse drug reaction risk in fluoropyrimidine-treated patients. Curr. Issues Mol. Biol. 2024 46 9 9831 9843 10.3390/cimb46090584 39329936
    [Google Scholar]
  9. Tong Z. Cheng M. Yu Y. Yu J. Yin Y. Liu J. Zhang S. Jiang S. Dong M. Correlation between pharmacokinetic parameters of 5-fluorouracil and related metabolites and adverse reactions in East-Asian patients with advanced colorectal cancer. Cancer Chemother. Pharmacol. 2022 89 3 323 330 10.1007/s00280‑021‑04387‑y 35067736
    [Google Scholar]
  10. Azwar S. Seow H.F. Abdullah M. Faisal Jabar M. Mohtarrudin N. Recent updates on mechanisms of resistance to 5-fluorouracil and reversal strategies in colon cancer treatment. Biology 2021 10 9 854 10.3390/biology10090854 34571731
    [Google Scholar]
  11. Dolat M. Macaire P. Goirand F. Vincent J. Hennequin A. Palmier R. Bengrine-Lefevre L. Ghiringhelli F. Royer B. Schmitt A. Association of 5-FU therapeutic drug monitoring to DPD phenotype assessment may reduce 5-FU under-exposure. Pharmaceuticals 2020 13 11 416 10.3390/ph13110416 33238487
    [Google Scholar]
  12. Kallee G. Milano G. Duffaud F. Dahan L. Ciccolini J. DPD ultra‐rapid metabolizer status and efficacy of 5‐fluorouracil treatment: A real‐world study. Fundam. Clin. Pharmacol. 2025 39 4 e70035 10.1111/fcp.70035 40623917
    [Google Scholar]
  13. Shiga T. Hiraide M. Cardiotoxicities of 5-fluorouracil and other fluoropyrimidines. Curr. Treat. Options Oncol. 2020 21 4 27 10.1007/s11864‑020‑0719‑1 32266582
    [Google Scholar]
  14. Bouali I. Dridi I. Gadacha W. Aouam K. Hassine M. El-Bok S. Boughattas N. Ben-Attia M. Zaeid S. Souli A. Circadian variation in hematotoxicity of the antineoplastic agent “5 Fluorouracil (5 FU)” in female rats and its relevance to chronotherapy. Biol. Rhythm Res. 2023 54 4 419 436 10.1080/09291016.2023.2206088
    [Google Scholar]
  15. Garcia R.M. Mobilia M. Newcomer J.B. Wilson C.L. Focal neurotoxicity associated with topical 5-fluorouracil. Cureus 2024 16 2 e54365 10.7759/cureus.54365 38500891
    [Google Scholar]
  16. Antoniotti C. Rossini D. Pietrantonio F. Salvatore L. Lonardi S. Tamberi S. Marmorino F. Moretto R. Prisciandaro M. Tamburini E. Tortora G. Passardi A. Bergamo F. Raimondi A. Ritorto G. Borelli B. Conca V. Ugolini C. Aprile G. Antonuzzo L. Gelsomino F. Martinelli E. Pella N. Masi G. Boni L. Galon J. Cremolini C. Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: Updated and overall survival results of the ATEZOTRIBE study. J. Clin. Oncol. 2024 42 22 2637 2644 10.1200/JCO.23.02728 38865678
    [Google Scholar]
  17. Liang Y.Y. Bacanu S. Sreekumar L. Ramos A.D. Dai L. Michaelis M. Cinatl J. Seki T. Cao Y. Coffill C.R. Lane D.P. Prabhu N. Nordlund P. CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity. Cell Chem. Biol. 2022 29 4 572 585.e8 10.1016/j.chembiol.2021.06.007 34265272
    [Google Scholar]
  18. Pawłowski P.H. Szczęsny P. Rempoła B. Poznańska A. Poznański J. Combined in silico and 19F NMR analysis of 5-fluorouracil metabolism in yeast at low ATP conditions. Biosci. Rep. 2019 39 12 BSR20192847 10.1042/BSR20192847 31742586
    [Google Scholar]
  19. Dasari M. Pelly S.C. Geng J. Gold H.B. Pribut N. Sharma S.K. D’Erasmo M.P. Bartsch P.W. Sun C. Toti K. Arnold R.S. Petros J.A. Xu L. Jiang Y. Miller E.J. Liotta D.C. Discovery of 5′-substituted 5-fluoro-2′-deoxyuridine monophosphate analogs: A novel class of thymidylate synthase inhibitors. ACS Pharmacol. Transl. Sci. 2023 6 5 702 709 10.1021/acsptsci.2c00252 37200809
    [Google Scholar]
  20. Vodenkova S. Buchler T. Cervena K. Veskrnova V. Vodicka P. Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol. Ther. 2020 206 107447 10.1016/j.pharmthera.2019.107447 31756363
    [Google Scholar]
  21. Gmeiner W.H. Okechukwu C.C. Review of 5-FU resistance mechanisms in colorectal cancer: Clinical significance of attenuated on-target effects. Cancer Drug Resist. 2023 6 2 257 272 10.20517/cdr.2022.136 37457133
    [Google Scholar]
  22. Bré J. Dickson A.L. Read O.J. Zhang Y. McKissock F.G. Mullen P. Tang P. Zickuhr G.M. Czekster C.M. Harrison D.J. The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent. Cancer Chemother. Pharmacol. 2023 91 5 401 412 10.1007/s00280‑023‑04528‑5 37000221
    [Google Scholar]
  23. Mori R. Ukai J. Tokumaru Y. Niwa Y. Futamura M. The mechanism underlying resistance to 5 fluorouracil and its reversal by the inhibition of thymidine phosphorylase in breast cancer cells. Oncol. Lett. 2022 24 3 311 10.3892/ol.2022.13431 35949616
    [Google Scholar]
  24. Khalili E. Afgar A. Rajabpour A. Aghaee-Bakhtiari S.H. Jamialahmadi K. Teimoori-Toolabi L. MiR-548c-3p through suppressing Tyms and Abcg2 increases the sensitivity of colorectal cancer cells to 5-fluorouracil. Heliyon 2023 9 11 e21775 10.1016/j.heliyon.2023.e21775 38045156
    [Google Scholar]
  25. Alzahrani S. Al Doghaither H. Al-ghafari A. Pushparaj P. 5 Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review). Oncol. Rep. 2023 50 4 175 10.3892/or.2023.8612 37594133
    [Google Scholar]
  26. Ghoshal K. Jacob S.T. An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem. Pharmacol. 1997 53 11 1569 1575 10.1016/S0006‑2952(97)00040‑3 9264308
    [Google Scholar]
  27. Doong S.L. Dolnick B.J. 5-Fluorouracil substitution alters pre-mRNA splicing in vitro. J. Biol. Chem. 1988 263 9 4467 4473 10.1016/S0021‑9258(18)68949‑5 3346255
    [Google Scholar]
  28. Chalabi-Dchar M. Fenouil T. Machon C. Vincent A. Catez F. Marcel V. Mertani H.C. Saurin J.C. Bouvet P. Guitton J. Venezia N.D. Diaz J.J. A novel view on an old drug, 5-fluorouracil: An unexpected RNA modifier with intriguing impact on cancer cell fate. NAR Cancer 2021 3 3 zcab032 10.1093/narcan/zcab032 34409299
    [Google Scholar]
  29. Thomas D.M. Zalcberg J.R. 5-fluorouracil: A pharmacological paradigm in the use of cytotoxics. Clin. Exp. Pharmacol. Physiol. 1998 25 11 887 895 10.1111/j.1440‑1681.1998.tb02339.x 9807659
    [Google Scholar]
  30. Radenković N. Nikodijević D. Jovankić J. Blagojević S. Milutinović M. Resistance to 5-fluorouracil: The molecular mechanisms of development in colon cancer cells. Eur. J. Pharmacol. 2024 983 176979 10.1016/j.ejphar.2024.176979 39241942
    [Google Scholar]
  31. Fattahi S.H. Jahandideh A. Akbarzadeh A. Preparation and in vitro evaluation of 5-fluorouracil-loaded PCL nanoparticles for breast cancer treatment. Bionanoscience 2024 14 2 1196 1205 10.1007/s12668‑024‑01318‑y
    [Google Scholar]
  32. Jahan S. Sultana N. Ali A. Emad N.A. Alam P. Mujeeb M. Aqil M. Ali A. 5-Fluorouracil- and sesamol-loaded transliposomal gel for skin cancer: In vitro, ex vivo, and dermatokinetic evaluation. ACS Omega 2025 10 7 6857 6875 10.1021/acsomega.4c09147 40028080
    [Google Scholar]
  33. Moodley T. Singh M. Polymeric mesoporous silica nanoparticles for enhanced delivery of 5-fluorouracil in vitro. Pharmaceutics 2019 11 6 288 10.3390/pharmaceutics11060288 31248179
    [Google Scholar]
  34. Liu J. Zhang J. Gao Y. Jiang Y. Guan Z. Xie Y. Hu J. Chen J. Barrier permeation and improved nanomedicine delivery in tumor microenvironments. Cancer Lett. 2023 562 216166 10.1016/j.canlet.2023.216166 37028698
    [Google Scholar]
  35. Vargason A.M. Anselmo A.C. Mitragotri S. The evolution of commercial drug delivery technologies. Nat. Biomed. Eng. 2021 5 9 951 967 10.1038/s41551‑021‑00698‑w 33795852
    [Google Scholar]
  36. de Souza M.M. Gini A.L.R. Moura J.A. Scarim C.B. Chin C.M. dos Santos J.L. Prodrug approach as a strategy to enhance drug permeability. Pharmaceuticals 2025 18 3 297 10.3390/ph18030297 40143076
    [Google Scholar]
  37. Fralish Z. Chen A. Khan S. Zhou P. Reker D. The landscape of small-molecule prodrugs. Nat. Rev. Drug Discov. 2024 23 5 365 380 10.1038/s41573‑024‑00914‑7 38565913
    [Google Scholar]
  38. Kim C.G. Jose J. Hay M.P. Choi P.J. Novel prodrug strategies for the treatment of tuberculosis. Chem. Asian J. 2024 19 23 e202400944 10.1002/asia.202400944 39179514
    [Google Scholar]
  39. Subbaiah M.A.M. Rautio J. Meanwell N.A. Prodrugs as empowering tools in drug discovery and development: Recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates. Chem. Soc. Rev. 2024 53 4 2099 2210 10.1039/D2CS00957A 38226865
    [Google Scholar]
  40. Chu B. Deng H. Niu T. Qu Y. Qian Z. Stimulus‐responsive nano‐prodrug strategies for cancer therapy: A focus on camptothecin delivery. Small Methods 2024 8 8 2301271 10.1002/smtd.202301271 38085682
    [Google Scholar]
  41. Zhou G. Exploring ester prodrugs: A comprehensive review of approaches, applications, and methods. Pharmacol. Pharm. 2024 15 8 269 284 10.4236/pp.2024.158016
    [Google Scholar]
  42. Ciaffaglione V. Modica M.N. Pittalà V. Romeo G. Salerno L. Intagliata S. Mutual prodrugs of 5‐fluorouracil: From a classic chemotherapeutic agent to novel potential anticancer drugs. ChemMedChem 2021 16 23 3496 3512 10.1002/cmdc.202100473 34415107
    [Google Scholar]
  43. Weiss J.T. Fraser C. Rubio-Ruiz B. Myers S.H. Crispin R. Dawson J.C. Brunton V.G. Patton E.E. Carragher N.O. Unciti-Broceta A. N-alkynyl derivatives of 5-fluorouracil: Susceptibility to palladium-mediated dealkylation and toxigenicity in cancer cell culture. Front Chem. 2014 2 56 10.3389/fchem.2014.00056 25121087
    [Google Scholar]
  44. Cardona-G W. Herrera-R A. Castrillón-L W. Ramírez-Malule H. Chemistry and anticancer activity of hybrid molecules and derivatives based on 5-fluorouracil. Curr. Med. Chem. 2021 28 27 5551 5601 10.2174/0929867328666210211164314 33573546
    [Google Scholar]
  45. Wang C. Zhang Z. Liu Z. Radiotherapy-activated prodrug: Past, present and beyond. ACS Cent. Sci. 2025 11 8 1306 1320 10.1021/acscentsci.5c00875 40893960
    [Google Scholar]
  46. Ahmad N. Albassam A.A. Faiyaz Khan M. Ullah Z. Mohammed Buheazah T. Salman AlHomoud H. Ali Al-Nasif H. A novel 5-Fluorocuracil multiple-nanoemulsion used for the enhancement of oral bioavailability in the treatment of colorectal cancer. Saudi J. Biol. Sci. 2022 29 5 3704 3716 10.1016/j.sjbs.2022.02.017 35844373
    [Google Scholar]
  47. Hmingthansanga V. Singh N. Banerjee S. Manickam S. Velayutham R. Natesan S. Improved topical drug delivery: Role of permeation enhancers and advanced approaches. Pharmaceutics 2022 14 12 2818 10.3390/pharmaceutics14122818 36559311
    [Google Scholar]
  48. Lindner S. Keim S. Haddadzadegan S. Fernandez Romero O. Zöller K. Stern G. Cesi I. Kafedjiiski K. Bernkop-Schnürch A. Strategies to improve the lipophilicity of hydrophilic macromolecular drugs. Adv. Healthc. Mater. 2025 e03721 10.1002/adhm.202503721 41097846
    [Google Scholar]
  49. Cada D.J. Mbogu U. Bindler R.J. Baker D.E. Uridine triacetate. Hosp. Pharm. 2016 51 6 484 488 10.1310/hpj51.06‑484 27354750
    [Google Scholar]
  50. Sabra R. Kirby D. Chouk V. Malgorzata K. Mohammed A.R. Buccal absorption of biopharmaceutics classification system III drugs: Formulation approaches and mechanistic insights. Pharmaceutics 2024 16 12 1563 10.3390/pharmaceutics16121563 39771541
    [Google Scholar]
  51. Kumar B. Priyadarshi R. Deeba F. Kulshreshtha A. Kumar A. Agrawal G. Gopinath P. Negi Y.S. Redox responsive xylan SS curcumin prodrug nanoparticles for dual drug delivery in cancer therapy. Mater. Sci. Eng. C 2020 107 110356 10.1016/j.msec.2019.110356 31761247
    [Google Scholar]
  52. Zhang R. Song X.Q. Liu R.P. Ma Z.Y. Xu J.Y. Fuplatin: An efficient and low-toxic dual-prodrug. J. Med. Chem. 2019 62 9 4543 4554 10.1021/acs.jmedchem.9b00128 31002510
    [Google Scholar]
  53. Singh M. Afonso J. Sharma D. Gupta R. Kumar V. Rani R. Baltazar F. Kumar V. Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics? Semin. Cancer Biol. 2023 90 1 14 10.1016/j.semcancer.2023.01.007 36706846
    [Google Scholar]
  54. Sun Y. Zhao D. Wang G. Jiang Q. Guo M. Kan Q. He Z. Sun J. A novel oral prodrug-targeting transporter MCT 1: 5-fluorouracil-dicarboxylate monoester conjugates. Asian J. Pharm. Sci. 2019 14 6 631 639 10.1016/j.ajps.2019.04.001 32104489
    [Google Scholar]
  55. Gupta N. Gupta G.D. Razdan K. Albekairi N.A. Alshammari A. Singh D. Development of nanoemulgel of 5-Fluorouracil for skin melanoma using glycyrrhizin as a penetration enhancer. Saudi Pharm. J. 2024 32 4 101999 10.1016/j.jsps.2024.101999 38454919
    [Google Scholar]
  56. Goswami A. Kohata A. Okazoe T. Huang H. Aida T. Fluoro-crown ether phosphate as efficient cell-permeable drug carrier by disrupting hydration layer. J. Am. Chem. Soc. 2024 146 33 23406 23411 10.1021/jacs.4c06464 39082642
    [Google Scholar]
  57. Bonet-Aleta J. Calzada-Funes J. Hueso J.L. Manganese oxide nano-platforms in cancer therapy: Recent advances on the development of synergistic strategies targeting the tumor microenvironment. Appl. Mater. Today 2022 29 101628 10.1016/j.apmt.2022.101628
    [Google Scholar]
  58. Nazli A. Irshad Khan M.Z. Rácz Á. Béni S. Acid-sensitive prodrugs; A promising approach for site-specific and targeted drug release. Eur. J. Med. Chem. 2024 276 116699 10.1016/j.ejmech.2024.116699 39089000
    [Google Scholar]
  59. Martin H. Lázaro L.R. Gunnlaugsson T. Scanlan E.M. Glycosidase activated prodrugs for targeted cancer therapy. Chem. Soc. Rev. 2022 51 23 9694 9716 10.1039/D2CS00379A 36349720
    [Google Scholar]
  60. Fu X. Hu X. Ultrasound-controlled prodrug activation: Emerging strategies in polymer mechanochemistry and sonodynamic therapy. ACS Appl. Bio Mater. 2024 7 12 8040 8058 10.1021/acsabm.4c00150 38698527
    [Google Scholar]
  61. Moradi Kashkooli F. Soltani M. Souri M. Controlled anti-cancer drug release through advanced nano-drug delivery systems: Static and dynamic targeting strategies. J. Control. Release 2020 327 316 349 10.1016/j.jconrel.2020.08.012 32800878
    [Google Scholar]
  62. Li G. Song Z. Ru Y. Zhang J. Luo L. Yang W. Wu H. Jin H. Bao X. Wei D. Yan Z. Qu H. Zhu Z. Xue X. Zhou G. Small‐molecule nanoprodrug with high drug loading and EGFR, PI3K/AKT dual‐inhibiting properties for bladder cancer treatment. Exploration 2023 3 5 20220141 10.1002/EXP.20220141 37933289
    [Google Scholar]
  63. Fu Q. Shen S. Sun P. Gu Z. Bai Y. Wang X. Liu Z. Bioorthogonal chemistry for prodrug activation in vivo. Chem. Soc. Rev. 2023 52 22 7737 7772 10.1039/D2CS00889K 37905601
    [Google Scholar]
  64. Deng C. Zheng M. Han S. Wang Y. Xin J. Aras O. Cheng L. An F. GSH‐activated porphyrin sonosensitizer prodrug for fluorescence imaging‐guided cancer sonodynamic therapy. Adv. Funct. Mater. 2023 33 32 2300348 10.1002/adfm.202300348 38045635
    [Google Scholar]
  65. Sharma A. Verwilst P. Li M. Ma D. Singh N. Yoo J. Kim Y. Yang Y. Zhu J.H. Huang H. Hu X.L. He X.P. Zeng L. James T.D. Peng X. Sessler J.L. Kim J.S. Theranostic fluorescent probes. Chem. Rev. 2024 124 5 2699 2804 10.1021/acs.chemrev.3c00778 38422393
    [Google Scholar]
  66. Yang R. Ouyang Z. Guo H. Qu J. Xia J. Shen M. Shi X. Microfluidic synthesis of intelligent nanoclusters of ultrasmall iron oxide nanoparticles with improved tumor microenvironment regulation for dynamic MR imaging-guided tumor photothermo-chemo-chemodynamic therapy. Nano Today 2022 46 101615 10.1016/j.nantod.2022.101615
    [Google Scholar]
  67. Mohammed M.H. Jasim A.M. Synthesis of 5‐fluorouracil-naproxen conjugates as a mutual prodrug for targeting cancer tissues. Macromol. Symp. 2022 401 1 2100308 10.1002/masy.202100308
    [Google Scholar]
  68. Huang D. Yin J. Zou Y. Huang H. Long S. Sun W. Du J. Fan J. Peng X. A self‐reinforced activatable photosensitizer prodrug enabling synergistic photodynamic and chemotherapy. Smart Molecules 2024 2 4 e20240005 10.1002/smo.20240005 40626272
    [Google Scholar]
  69. Zheng F. Fan D. Yao H. Ding J. Huang S. Fang Y. Dong J. Chen F. Zeng W. Synergistic photodynamic and chemodynamic therapy for tumor treatment using a glutathione-activated photosensitizer with near-infrared (NIR) imaging. ACS Mater. Lett. 2024 6 10 4673 4681 10.1021/acsmaterialslett.4c01400
    [Google Scholar]
  70. Tafech A. Stéphanou A. On the importance of acidity in cancer cells and therapy. Biology 2024 13 4 225 10.3390/biology13040225 38666837
    [Google Scholar]
  71. Bargakshatriya R. Pramanik S.K. Leading prodrug strategies for targeted and specific release. Future Med. Chem. 2025 17 8 865 868 10.1080/17568919.2025.2479412 40085509
    [Google Scholar]
  72. Li N. Zhang L. Sun K. Liu J. Wang Z. Wang Y. Lu H. Xiang W. Yang H. Tang R. Yan G. pH-sensitive nanodrug self-assembled from aliphatic 5-fluorouracil derivative and doxorubicin for synergistic cancer therapy. ACS Appl. Nano Mater. 2024 7 9 10419 10428 10.1021/acsanm.4c00866
    [Google Scholar]
  73. Baiula M. Cirillo M. Martelli G. Giraldi V. Gasparini E. Anelli A.C. Spampinato S.M. Giacomini D. Selective integrin ligands promote cell internalization of the antineoplastic agent fluorouracil. ACS Pharmacol. Transl. Sci. 2021 4 5 1528 1542 10.1021/acsptsci.1c00094 34661072
    [Google Scholar]
  74. Su Z. Xiao D. Xie F. Liu L. Wang Y. Fan S. Zhou X. Li S. Antibody-drug conjugates: Recent advances in linker chemistry. Acta Pharm. Sin. B 2021 11 12 3889 3907 10.1016/j.apsb.2021.03.042 35024314
    [Google Scholar]
  75. Wei D. Wang H. Huangfu S. Qi C. Jiang Y. Yu X. Jiang B. Chen H. Fine-tuning phenoxy silyl scaffolds for the development of glutathione-responsive prodrugs and antibody-drug conjugates. Bioorg. Med. Chem. 2025 120 118088 10.1016/j.bmc.2025.118088 39914224
    [Google Scholar]
  76. Bomba H.N. Fulton M.D. Savoy E.A. Langton-Webster B. Berkman C.E. A unique prodrug targeting the prostate-specific membrane antigen for the delivery of monomethyl auristatin E. Bioconjug. Chem. 2025 36 2 169 178 10.1021/acs.bioconjchem.4c00297 39881600
    [Google Scholar]
  77. Savoy E.A. Olatunji F.P. Yoon H. Mesbahi N. Knight J.R. Berkman C.E. Acid-labile Linkers. Chemical Linkers in Antibody-Drug Conjugates (ADCs). van Delft F. Lambert J.M. The Royal Society of Chemistry 2021 213 231 10.1039/9781839165153‑00213
    [Google Scholar]
  78. Li H. Shen X. Chu Y. Yuan P. Shuai Q. Challenging and new opportunities for prodrug technology. Invest. New Drugs 2025 43 2 365 376 10.1007/s10637‑025‑01515‑w 39966300
    [Google Scholar]
  79. Hao Y. Liu T. Zhou H. Xu R. Li K. Chen M. Chen Y. Oxygen-supplying ROS-responsive prodrug for synergistic chemotherapy and photodynamic therapy of colon cancer. Front. Pharmacol. 2024 15 1325544 10.3389/fphar.2024.1325544 38420201
    [Google Scholar]
  80. Wu Y. Chen W. Wang C. Xing D. Nanozyme-activating prodrug therapies: A review. Chin. Chem. Lett. 2024 35 2 109096 10.1016/j.cclet.2023.109096
    [Google Scholar]
  81. Sarbadhikary P. George B.P. Abrahamse H. Recent advances in photosensitizers as multifunctional theranostic agents for imaging-guided photodynamic therapy of cancer. Theranostics 2021 11 18 9054 9088 10.7150/thno.62479 34522227
    [Google Scholar]
  82. Xu N. Xu F. Yao Y. Zhang C. Sun W. Du J. Fan J. Peng X. A GSH-activated photosensitizer prodrug for fluorescence imaging-guided chemo-photodynamic therapy. Sens. Actuators B Chem. 2024 410 135664 10.1016/j.snb.2024.135664
    [Google Scholar]
  83. Horo H. Das S. Mandal B. Kundu L.M. Development of a photoresponsive chitosan conjugated prodrug nano-carrier for controlled delivery of antitumor drug 5-fluorouracil. Int. J. Biol. Macromol. 2019 121 1070 1076 10.1016/j.ijbiomac.2018.10.095 30342947
    [Google Scholar]
  84. Das S. Verma K. Dubey V.K. Kundu L.M. Fabrication of nanoparticles from a synthesized peptide amphiphile as a versatile therapeutic cargo for high antiproliferative activity in tumor cells. Bioorg. Chem. 2020 94 103440 10.1016/j.bioorg.2019.103440 31780302
    [Google Scholar]
  85. Ai Y. Obianom O.N. Kuser M. Li Y. Shu Y. Xue F. Enhanced tumor selectivity of 5-fluorouracil using a reactive oxygen species-activated prodrug approach. ACS Med. Chem. Lett. 2019 10 1 127 131 10.1021/acsmedchemlett.8b00539 30655959
    [Google Scholar]
  86. Adam C. Bray T.L. Pérez-López A.M. Tan E.H. Rubio-Ruiz B. Baillache D.J. Houston D.R. Salji M.J. Leung H.Y. Unciti-Broceta A.A. 5-FU precursor designed to evade anabolic and catabolic drug pathways and activated by Pd chemistry in vitro and in vivo. J. Med. Chem. 2022 65 1 552 561 10.1021/acs.jmedchem.1c01733 34979089
    [Google Scholar]
  87. Badirujjaman M. Thummer R.P. Bhabak K.P. Esterase‐responsive self‐immolative prodrugs for the sustained delivery of the anticancer drug 5‐fluorouracil with turn‐on fluorescence. Chem. Asian J. 2025 20 2 e202400846 10.1002/asia.202400846 39484866
    [Google Scholar]
  88. Tyagi K. Kumari R. Venkatesh V. Alkaline phosphatase (ALP) activatable small molecule-based prodrugs for cancer theranostics. Org. Biomol. Chem. 2023 21 21 4455 4464 10.1039/D3OB00510K 37191120
    [Google Scholar]
  89. Kumar S.K.B. Kandula M. Sivanesan P. Preclinical evaluation of CLX-155, a novel prodrug of 5-FU for the treatment of cancer. J. Clin. Oncol. 2020 38 Suppl. 15 e15614 10.1200/JCO.2020.38.15_suppl.e15614
    [Google Scholar]
  90. Salerno L. Sorrenti V. Pittalà V. Consoli V. Modica M.N. Romeo G. Marrazzo A. Giuliano M. Zajdel P. Vanella L. Intagliata S. Discovery of SI 1/20 and SI 1/22 as mutual prodrugs of 5‐fluorouracil and imidazole‐based heme oxygenase 1 inhibitor with improved cytotoxicity in DU145 prostate cancer cells. ChemMedChem 2023 18 8 e202300047 10.1002/cmdc.202300047 36756924
    [Google Scholar]
  91. Alhaidari L.M. Spain S.G. Synthesis of 5-fluorouracil polymer conjugate and 19F NMR analysis of drug release for MRI monitoring. Polymers 2023 15 7 1778 10.3390/polym15071778 37050392
    [Google Scholar]
  92. Elferink H. Titulaer W.H.C. Derks M.G.N. Veeneman G.H. Rutjes F.P.J.T. Boltje T.J. Chloromethyl glycosides as versatile synthons to prepare glycosyloxymethyl‐prodrugs. Chemistry 2022 28 9 e202103910 10.1002/chem.202103910 35045197
    [Google Scholar]
  93. Bhattacharya S. An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer. Crit. Rev. Oncol. Hematol. 2023 183 103916 10.1016/j.critrevonc.2023.103916 36717006
    [Google Scholar]
  94. Zou T. Huang Y. Zhou Z. He S. Liu J. Chen Y. Liu H. Luo Z. Liu M. Wei H. Yu C. A minimalist multifunctional nano-prodrug for drug resistance reverse and integration with PD-L1 mAb for enhanced immunotherapy of hepatocellular carcinoma. J. Nanobiotechnology 2024 22 1 750 10.1186/s12951‑024‑03027‑w 39627819
    [Google Scholar]
  95. Won H.J. Ha T.K. Kwon S.J. Cho H.Y. Hur S.J. Baik H.H. Suh S.I. Ha E. Kim Y.H. Differential effects of 5-fluorouracil on glucose transport and expressions of glucose transporter proteins in gastric cancer cells. Anticancer Drugs 2010 21 3 270 276 10.1097/CAD.0b013e328334562c 20023572
    [Google Scholar]
  96. Chang C.K. Chiu P.F. Yang H.Y. Juang Y.P. Lai Y.H. Lin T.S. Hsu L.C. Yu L.C.H. Liang P.H. Targeting colorectal cancer with conjugates of a glucose transporter inhibitor and 5-fluorouracil. J. Med. Chem. 2021 64 8 4450 4461 10.1021/acs.jmedchem.0c00897 33819035
    [Google Scholar]
  97. Xiu T. Guo Q. Jing F. Shi Y. Jing F. CD13 downregulation mediated by ubenimex inhibits autophagy to overcome 5-FU resistance by disturbing the EMP3/FAK/NF-κB pathway in gastric cancer cells. Transl. Cancer Res. 2022 11 8 2487 2500 10.21037/tcr‑22‑345 36093528
    [Google Scholar]
  98. Yue K. Hou X. Jia G. Zhang L. Zhang J. Tan L. Wang X. Zhang Z. Li P. Xu W. Li X. Jiang Y. Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy. Bioorg. Chem. 2021 116 105343 10.1016/j.bioorg.2021.105343 34544027
    [Google Scholar]
  99. Bhatia M. Devi S. Co-crystallization: A green approach for the solubility enhancement of poorly soluble drugs. CrystEngComm 2024 26 3 293 311 10.1039/D3CE01047C
    [Google Scholar]
  100. Kalantri S.S. Yadav M.D. Advances in carbamazepine cocrystals: A review. Cryst. Res. Technol. 2024 59 4 2300296 10.1002/crat.202300296
    [Google Scholar]
  101. Saha A. Ahangar A.A. Dar A.A. Thirunahari S. Parambil J.V. Pharmaceutical cocrystals: A perspective on development and scale-up of solution cocrystallization. Cryst. Growth Des. 2023 23 11 7558 7581 10.1021/acs.cgd.2c01553
    [Google Scholar]
  102. Khan S. Zahoor M. Rahman M.U. Gul Z. Cocrystals; basic concepts, properties and formation strategies. Z. Phys. Chem. 2023 237 3 273 332 10.1515/zpch‑2022‑0175
    [Google Scholar]
  103. Nugrahani I. Jessica M.A. Amino acids as the potential co-former for co-crystal development: A review. Molecules 2021 26 11 3279 10.3390/molecules26113279 34071731
    [Google Scholar]
  104. Yang X. Zhu J. Chen Z. Chen B. Jin S. Liu B. Wang D. Seven cocrystals of pyrazinamide and organic acids by H-bonds and some noncovalent associations. J. Mol. Struct. 2022 1250 131770 10.1016/j.molstruc.2021.131770
    [Google Scholar]
  105. Ding P. Liu Z. Wu Y. Zong C. Wang Y. Xu Y. Xu K. Wang L. Preparation, structure characterization and solubility of one cocrystal and one salt of Imatinib with Citric acid and Fumaric acid. J. Mol. Struct. 2025 1333 141769 10.1016/j.molstruc.2025.141769
    [Google Scholar]
  106. Gosecka M. Jaworska-Krych D. Gosecki M. Urbaniak M. Wielgus E. Gostynski B. Marcinkowska M. Janaszewska A. Klajnert-Maculewicz B. Construction of dynamic hydrogel inducing effective and selective 5-fluorouracil monotherapy against cervical cancer cells. ACS Appl. Mater. Interfaces 2025 17 9 13427 13444 10.1021/acsami.4c20276 39982379
    [Google Scholar]
  107. Das B. Baidya A.T.K. Mathew A.T. Yadav A.K. Kumar R. Structural modification aimed for improving solubility of lead compounds in early phase drug discovery. Bioorg. Med. Chem. 2022 56 116614 10.1016/j.bmc.2022.116614 35033884
    [Google Scholar]
  108. Barlow N. Chalmers D.K. Williams-Noonan B.J. Thompson P.E. Norton R.S. Improving membrane permeation in the beyond rule-of-five space by using prodrugs to mask hydrogen bond donors. ACS Chem. Biol. 2020 15 8 2070 2078 10.1021/acschembio.0c00218 32628005
    [Google Scholar]
  109. Li S. Liu M. Yang D. Zhang L. Lu Y. Du G. Research and prospects on the evaluation of drug cocrystal permeability. Int. J. Drug Discov. Pharmacol. 2025 4 1 100005 10.53941/ijddp.2025.100005
    [Google Scholar]
  110. Hao H. Zhang Y. Hu X. Guo W. Yang C. Wang J. Cocrystallization of 5-fluorouracil with gallic acid: A novel 5-fluorouracil cocrystal displaying synergistic anti-tumor activity both in oral and intraperitoneal injection administration. Eur. J. Pharm. Biopharm. 2023 187 12 23 10.1016/j.ejpb.2023.04.001 37031731
    [Google Scholar]
  111. Samie A. Alavian H. A perspective on the permeability of cocrystals/organic salts of oral drugs. Mol. Pharm. 2024 21 10 4860 4911 10.1021/acs.molpharmaceut.4c00786 39284012
    [Google Scholar]
  112. Dai X.L. Voronin A.P. Gao W. Perlovich G.L. Lu T.B. Chen J.M. Intermolecular interactions and permeability of 5-fluorouracil cocrystals with a series of isomeric hydroxybenzoic acids: A combined theoretical and experimental study. CrystEngComm 2019 21 34 5095 5105 10.1039/C9CE00661C
    [Google Scholar]
  113. Dai X.L. Wu C. Li J.H. Liu L.C. He X. Lu T.B. Chen J-M. Modulating the solubility and pharmacokinetic properties of 5-fluorouracil via cocrystallization. CrystEngComm 2020 22 21 3670 3682 10.1039/D0CE00409J
    [Google Scholar]
  114. Yu Y.M. Niu Y.Y. Wang L.Y. Li Y.T. Wu Z.Y. Yan C.W. Supramolecular self-assembly and perfected in vitro/vivo property of 5-fluorouracil and ferulic acid on the strength of double optimized strategy: The first 5-fluorouracial-phenolic acid nutraceutical cocrystal with synergistic antitumor efficacy. Analyst 2021 146 8 2506 2519 10.1039/D1AN00171J 33899060
    [Google Scholar]
  115. Yu Y.M. Liu L. Bu F.Z. Li Y.T. Yan C.W. Wu Z.Y. A novice cocrystal nanomicelle formulation of 5-fluorouracil with proline: The design, self-assembly and in vitro/vivo biopharmaceutical characteristics. Int. J. Pharm. 2022 617 121635 10.1016/j.ijpharm.2022.121635 35257803
    [Google Scholar]
  116. Yu Y.M. Wang L.Y. Bu F.Z. Wang L.L. Li Y.T. Wang C. Wu Z-Y. The supramolecular self-assembly of 5-fluorouracil and caffeic acid through cocrystallization strategy opens up a new way for the development of synergistic antitumor pharmaceutical cocrystal. CrystEngComm 2020 22 45 7992 8006 10.1039/D0CE01297A
    [Google Scholar]
  117. Aslam A. Parveen A. Bano N. Jabeen I. Hassan M. Aftab U. Hareem M. Jubeen F. Shawaf J. Nazir A. Iqbal M. Cocrystallization of 5-FU and novel sulfathiazole Schiff bases: Synthesis, theoretical and experimental anticancer evaluation against MCF-7 and SW-480 cancer cell lines. J. Mol. Liq. 2025 420 126850 10.1016/j.molliq.2025.126850
    [Google Scholar]
  118. Hao H. Ren T. Quan C. Wang J. Chiral 5-fluorouracil-arginine cocrystals screened by wet powder grinding method: Leading to synergistic anti-tumor and alleviate cardiotoxicity. Powder Technol. 2024 436 119487 10.1016/j.powtec.2024.119487
    [Google Scholar]
  119. Yildirim N. Icsel C. Ercan S. Aygun M. Yilmaz V.T. A novel cocrystal of 5-fluorouracil with 2,2′-dipyridylamine: Synthesis, structural characterization, thermal analysis and in silico anticancer evaluation as a thymidylate synthase inhibitor. J. Mol. Struct. 2024 1318 139310 10.1016/j.molstruc.2024.139310
    [Google Scholar]
  120. Jubeen F. Jabeen I. Aftab U. Noor S. Hareem M. Sultan M. Kazi M. Synthesis, characterization, theoretical and experimental anticancer evaluation of novel cocrystals of 5-fluorouracil and schiff bases against SW480 colorectal carcinoma. Pharmaceutics 2023 15 7 1929 10.3390/pharmaceutics15071929 37514115
    [Google Scholar]
  121. Kumar A. Novak J. Singh A.K. Singh H. Thareja S. Pathak P. Grishina M. Verma A. Kumar P. Virtual screening, structure based pharmacophore mapping, and molecular simulation studies of pyrido[2,3-d]pyrimidines as selective thymidylate synthase inhibitors. J. Biomol. Struct. Dyn. 2023 41 23 14197 14211 10.1080/07391102.2023.2208205 37154748
    [Google Scholar]
  122. Liu X. Ma X. Ou K. Wang Q. Gao L. Yang L. Real-world results of raltitrexed combined with S-1 and bevacizumab in heavily pretreated metastatic colorectal cancer. Cancer Manag. Res. 2023 15 277 289 10.2147/CMAR.S398539 36969545
    [Google Scholar]
  123. Sabri N.H. Halim S.N. Zain S.M. Lee V.S. Modification of anti-cancer co-crystal for thymidylate synthase inhibition: Molecular dynamics study. Chiang Mai J. Sci. 2018 45 2361 2373
    [Google Scholar]
  124. Sher F. Iqbal S.Z. Jubeen F. Future of 5-fluorouracil in cancer therapeutics, current pharmacokinetics issues and a way forward. J. Cancer Res. Pract. 2019 6 4 155 10.4103/JCRP.JCRP_10_19
    [Google Scholar]
  125. Alanazi S.A. Harisa G.I. Badran M.M. Haq N. Radwan A.A. Kumar A. Shakeel F. Alanazi F.K. Cholesterol-conjugate as a new strategy to improve the cytotoxic effect of 5-fluorouracil on liver cancer: Impact of liposomal composition. Curr. Drug Deliv. 2020 17 10 898 910 10.2174/1567201817666200211095452 32072911
    [Google Scholar]
  126. Javid H. Oryani M.A. Rezagholinejad N. Esparham A. Tajaldini M. Karimi-Shahri M. RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions. Cancer Med. 2024 13 2 e6800 10.1002/cam4.6800 38349028
    [Google Scholar]
  127. Kapoor D.U. Garg R. Gaur M. Pareek A. Prajapati B.G. Castro G.R. Suttiruengwong S. Sriamornsak P. Pectin hydrogels for controlled drug release: Recent developments and future prospects. Saudi Pharm. J. 2024 32 4 102002 10.1016/j.jsps.2024.102002 38439951
    [Google Scholar]
  128. Zhao B. Li L. Lv X. Du J. Gu Z. Li Z. Cheng L. Li C. Hong Y. Progress and prospects of modified starch-based carriers in anticancer drug delivery. J. Control. Release 2022 349 662 678 10.1016/j.jconrel.2022.07.024 35878730
    [Google Scholar]
  129. Wang Z. Li W. Jiang Y. Park J. Gonzalez K.M. Wu X. Zhang Q.Y. Lu J. Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery. Nat. Commun. 2024 15 1 2073 10.1038/s41467‑024‑46331‑7 38453918
    [Google Scholar]
  130. Sood A. Gupta A. Agrawal G. Recent advances in polysaccharides based biomaterials for drug delivery and tissue engineering applications. Carbohydr. Polym. Technol. Appl. 2021 2 100067 10.1016/j.carpta.2021.100067
    [Google Scholar]
  131. Ma N. Li R. You S. Zhang D.J. Preparation of novel sulfated polysaccharide-carboxymethyl-5-fluorouracil-folic acid conjugates for targeted anticancer drug delivery. Int. J. Biol. Macromol. 2024 273 Pt 1 133121 10.1016/j.ijbiomac.2024.133121 38876229
    [Google Scholar]
  132. Zhang Y. Palanisamy S. Kwon M.H. Ge Y. Kou F. Uthamapriya R.A. Lee D. Lee D.J. Bao H. You S. Zhang Y. A novel targeted anticancer drug delivery strategy: Cnidium officinale polysaccharide conjugated with carboxymethyl-5-fluorouracil and folic acid for ovarian cancer therapy. Int. J. Biol. Macromol. 2025 285 138107 10.1016/j.ijbiomac.2024.138107 39608520
    [Google Scholar]
  133. Wang Y. Yang Y. Zhu D. Zhang H. Wang Y. Preparation, characterization, and anticancer activity evaluation of Ganoderma lucidum polysaccharide/5-fluorouracil conjugate. Colloid Polym. Sci. 2025 303 8 1519 1529 10.1007/s00396‑025‑05414‑7
    [Google Scholar]
  134. Hu L. Meng T. Marabada D. Jin Z. Huang Q. Wei S. Wang Z. 5-Fluorouracil-β-Cyclodextrin conjugates: Linker strategies to enhance the anticancer efficacy and reduce the side effects. Carbohydr. Polym. Technol. Appl. 2025 9 100691 10.1016/j.carpta.2025.100691
    [Google Scholar]
  135. Cen J.H. Xie Q.H. Guo G.H. Xu S.Y. Liu Z.Y. Liao Y.H. Zhong X.P. Liu H.Y. Construction of 5-fluorouracil and gallium corrole conjugates for enhanced photodynamic therapy. J. Med. Chem. 2024 67 11 9054 9068 10.1021/acs.jmedchem.4c00249 38781403
    [Google Scholar]
  136. Shao W. Yang Y. Shen W. Ren L. WenwenWang; Zhu, P. Hyaluronic acid-conjugated methotrexate and 5-fluorouracil for targeted drug delivery. Int. J. Biol. Macromol. 2024 273 Pt 1 132671 10.1016/j.ijbiomac.2024.132671 38823747
    [Google Scholar]
  137. Wang Q. Wang C. Li S. Xiong Y. Wang H. Li Z. Wan J. Yang X. Li Z. Influence of linkers within stimuli-responsive prodrugs on cancer therapy: A case of five doxorubicin dimer-based nanoparticles. Chem. Mater. 2022 34 5 2085 2097 10.1021/acs.chemmater.1c03346
    [Google Scholar]
  138. Alvani A. Shayanfar A. Solution stability of pharmaceutical cocrystals. Cryst. Growth Des. 2022 22 10 6323 6337 10.1021/acs.cgd.2c00787
    [Google Scholar]
  139. Jing X. Hu H. Sun Y. Yu B. Cong H. Shen Y. The intracellular and extracellular microenvironment of tumor site: The trigger of stimuli‐responsive drug delivery systems. Small Methods 2022 6 3 2101437 10.1002/smtd.202101437 35048560
    [Google Scholar]
  140. Patel R. Barker J. ElShaer A. Pharmaceutical excipients and drug metabolism: A mini-review. Int. J. Mol. Sci. 2020 21 21 8224 10.3390/ijms21218224 33153099
    [Google Scholar]
  141. Du S. Wen Z. Yu J. Meng Y. Liu Y. Xia X. Breath and beyond: Advances in nanomedicine for oral and intranasal aerosol drug delivery. Pharmaceuticals 2024 17 12 1742 10.3390/ph17121742 39770584
    [Google Scholar]
  142. Teno J. Evtoski Z. Prieto C. Lagaron J.M. The development of a multilayer transdermal patch platform based on electrospun nanofibers for the delivery of caffeine. Pharmaceutics 2025 17 7 921 10.3390/pharmaceutics17070921 40733129
    [Google Scholar]
  143. Luo D. Liu X. Jiang L. Guo Z. Lv Y. Tian X. Wang X. Cui S. Wan S. Qu X. Xu X. Li X. Rational design, synthesis, and biological evaluation of novel S1PR2 antagonists for reversing 5-FU-resistance in colorectal cancer. J. Med. Chem. 2022 65 21 14553 14577 10.1021/acs.jmedchem.2c00958 36269639
    [Google Scholar]
  144. Luo D. Zhang Y. Yang S. Tian X. Lv Y. Guo Z. Liu X. Han G. Liu S. Wang W. Cui S. Qu X. Wan S. Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer. Eur. J. Med. Chem. 2021 225 113775 10.1016/j.ejmech.2021.113775 34411894
    [Google Scholar]
  145. Backer N. Kumar A. Singh A.K. Singh H. Narasimhan B. Kumar P. Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer. Drug Discov. Today 2024 29 1 103853 10.1016/j.drudis.2023.103853 38070703
    [Google Scholar]
  146. Sarre R. Dobrovolska O. Lundström P. Turcu D. Agback T. Halskau Ø. Isaksson J. Structural dynamics of human deoxyuridine 5′-triphosphate nucleotidohydrolase (dUTPase). Sci. Rep. 2024 14 1 26081 10.1038/s41598‑024‑76548‑x 39477983
    [Google Scholar]
  147. Araki H. Takenaka T. Takahashi K. Yamashita F. Matsuoka K. Yoshisue K. Ieiri I. A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS‐114. CPT Pharmacometrics Syst. Pharmacol. 2022 11 5 604 615 10.1002/psp4.12747 34951129
    [Google Scholar]
  148. Sim A.A.X.H. Cheam J.Y. Law J.W.F. Letchumanan V. Kumari Y. Ogawa S. Wong S.H. Chan K-G. Tan L.T-H. The ameliorative role of probiotics in 5-fluorouracil induced intestinal mucositis. Prog. Microbes Mol. Biol. 2023 6 1 a0000339 10.36877/pmmb.a0000339
    [Google Scholar]
  149. Roy S. Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J. Gastroenterol. 2023 29 14 2078 2100 10.3748/wjg.v29.i14.2078 37122604
    [Google Scholar]
  150. Teng Y. Zhao D. Yan C. Ren X. Wang A. Xia X. Pasteurized Akkermansia muciniphila improves immunity and relieves other toxic effects in 5-fluorouracil treated BALB/c mice. Food Biosci. 2024 59 103918 10.1016/j.fbio.2024.103918
    [Google Scholar]
  151. Yuan L. Zhang S. Li H. Yang F. Mushtaq N. Ullah S. Shi Y. An C. Xu J. The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer. Biomed. Pharmacother. 2018 108 184 193 10.1016/j.biopha.2018.08.165 30219675
    [Google Scholar]
  152. Wang J.L. Chen Y.S. Huang K.C. Yeh C.H. Chen M.C.M. Wu L.S.H. Chiu Y.H. Resistant starch-encapsulated probiotics attenuate colorectal cancer cachexia and 5-fluorouracil-induced microbial dysbiosis. Biomedicines 2024 12 7 1450 10.3390/biomedicines12071450 39062024
    [Google Scholar]
  153. Dong Y. Zhang K. Wei J. Ding Y. Wang X. Hou H. Wu J. Liu T. Wang B. Cao H. Gut microbiota-derived short-chain fatty acids regulate gastrointestinal tumor immunity: A novel therapeutic strategy? Front. Immunol. 2023 14 1158200 10.3389/fimmu.2023.1158200 37122756
    [Google Scholar]
  154. He Z. Dong H. The roles of short-chain fatty acids derived from colonic bacteria fermentation of non-digestible carbohydrates and exogenous forms in ameliorating intestinal mucosal immunity of young ruminants. Front. Immunol. 2023 14 1291846 10.3389/fimmu.2023.1291846 38149240
    [Google Scholar]
  155. Yue X. Wen S. Long-kun D. Man Y. Chang S. Min Z. Shuang-yu L. Xin Q. Jie M. Liang W. Three important short-chain fatty acids (SCFAs) attenuate the inflammatory response induced by 5-FU and maintain the integrity of intestinal mucosal tight junction. BMC Immunol. 2022 23 1 19 10.1186/s12865‑022‑00495‑3 35448938
    [Google Scholar]
  156. Tang X. Probiotic roles of Clostridium butyricum in piglets: Considering aspects of intestinal barrier function. Animals 2024 14 7 1069 10.3390/ani14071069 38612308
    [Google Scholar]
  157. Xie J. Li L. Dai T. Qi X. Wang Y. Zheng T. Gao X. Zhang Y. Ai Y. Ma L. Chang S. Luo F. Tian Y. Sheng J. Short‐chain fatty acids produced by ruminococcaceae mediate α‐linolenic acid promote intestinal stem cells proliferation. Mol. Nutr. Food Res. 2022 66 1 2100408 10.1002/mnfr.202100408 34708542
    [Google Scholar]
  158. Liu D. Xie L.S. Lian S. Li K. Yang Y. Wang W.Z. Hu S. Liu S.J. Liu C. He Z. Anaerostipes hadrus, a butyrate-producing bacterium capable of metabolizing 5-fluorouracil. MSphere 2024 9 4 e00816 e00823 10.1128/msphere.00816‑23 38470044
    [Google Scholar]
  159. Huang T.C. Peng K.C. Kuo T.T. Lin L.C. Liu B.C. Ye S.P. Chu C.C. Hsia S.M. Chang H.Y. Predicting agents that can overcome 5-FU resistance in colorectal cancers via pharmacogenomic analysis. Biomedicines 2021 9 8 882 10.3390/biomedicines9080882 34440086
    [Google Scholar]
  160. Wang Q. Shao X. Zhang Y. Zhu M. Wang F.X.C. Mu J. Li J. Yao H. Chen K. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med. 2023 12 10 11149 11165 10.1002/cam4.5698 36807772
    [Google Scholar]
  161. Wang X. Zhang H. Chen X. Wu C. Ding K. Sun G. Luo Y. Xiang D. Overcoming tumor microenvironment obstacles: Current approaches for boosting nanodrug delivery. Acta Biomater. 2023 166 42 68 10.1016/j.actbio.2023.05.043 37257574
    [Google Scholar]
  162. Chen C. Wang Z. Ding Y. Qin Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front. Immunol. 2023 14 1133308 10.3389/fimmu.2023.1133308 36845131
    [Google Scholar]
  163. Xu J.L. Yuan L. Hu C. Weng C.Y. Xu H.D. Shi Y.F. Huang L. Ying J.E. Xu Z.Y. Qin J.J. Cheng X.D. Trametes robiniophila murr sensitizes gastric cancer cells to 5-fluorouracil by modulating tumor microenvironment. Front. Pharmacol. 2022 13 911663 10.3389/fphar.2022.911663 35656301
    [Google Scholar]
  164. Wang Y-N. Gui M-B. Qu L-P. Zou M. Gao F. Astragalus polysaccharide inhibits IDO1 expression in colon tumor microenvironment to increase intratumoral CD8~+ T cell infiltration. Zhongguo Zhongyao Zazhi 2023 48 17 4722 4730 10.19540/j.cnki.cjcmm.20230510.705 37802811
    [Google Scholar]
  165. Huai M. Wang Y. Li J. Pan J. Sun F. Zhang F. Zhang Y. Xu L. Intelligent nanovesicle for remodeling tumor microenvironment and circulating tumor chemoimmunotherapy amplification. J. Nanobiotechnology 2024 22 1 257 10.1186/s12951‑024‑02467‑8 38755645
    [Google Scholar]
  166. Liu L. Chen G. Gong S. Huang R. Fan C. Targeting tumor-associated macrophage: An adjuvant strategy for lung cancer therapy. Front. Immunol. 2023 14 1274547 10.3389/fimmu.2023.1274547 38022518
    [Google Scholar]
  167. Nguyen H.T. Kan E.L. Humayun M. Gurvich N. Offeddu G.S. Wan Z. Coughlin M.F. Renteria D.C. Loew A. Wilson S. Zhang C. Vu V. Lee S.W.L. Tan S.L. Barbie D. Hsu J. Gillrie M.R. Kamm R.D. Patient-specific vascularized tumor model: Blocking monocyte recruitment with multispecific antibodies targeting CCR2 and CSF-1R. Biomaterials 2025 312 122731 10.1016/j.biomaterials.2024.122731 39153324
    [Google Scholar]
  168. Bess S.N. Greening G.J. Rajaram N. Muldoon T.J. Macrophage-targeted anti-CCL2 immunotherapy enhances tumor sensitivity to 5-fluorouracil in a Balb/c-CT26 murine colon carcinoma model measured using diffuse reflectance spectroscopy. BMC Immunol. 2022 23 1 20 10.1186/s12865‑022‑00493‑5 35461243
    [Google Scholar]
  169. Blondy S. David V. Verdier M. Mathonnet M. Perraud A. Christou N. 5‐Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes. Cancer Sci. 2020 111 9 3142 3154 10.1111/cas.14532 32536012
    [Google Scholar]
  170. Fan Z. Cui Y. Chen L. Liu P. Duan W. 23-Hydroxybetulinic acid attenuates 5-fluorouracil resistance of colorectal cancer by modulating M2 macrophage polarization via STAT6 signaling. Cancer Immunol. Immunother. 2024 73 5 83 10.1007/s00262‑024‑03662‑0 38554148
    [Google Scholar]
  171. Gong Y. Gao W. Zhang J. Dong X. Zhu D. Ma G. Engineering nanoparticles-enabled tumor-associated macrophages repolarization and phagocytosis restoration for enhanced cancer immunotherapy. J. Nanobiotechnology 2024 22 1 341 10.1186/s12951‑024‑02622‑1 38890636
    [Google Scholar]
  172. Liao L. Wang Y.X. Fan S.S. Hu Y.Y. Wang X.C. Zhang X. The role and clinical significance of tumor-associated macrophages in the epithelial-mesenchymal transition of lung cancer. Front. Oncol. 2025 15 1571583 10.3389/fonc.2025.1571583 40304000
    [Google Scholar]
  173. Long S. Wang J. Weng F. Xiang D. Sun G. Extracellular matrix protein 1 regulates colorectal cancer cell proliferative, migratory, invasive and epithelial-mesenchymal transition activities through the PI3K/AKT/GSK3β/snail signaling axis. Front. Oncol. 2022 12 889159 10.3389/fonc.2022.889159 35574325
    [Google Scholar]
  174. Long S. Wang J. Weng F. Pei Z. Zhou S. Sun G. Xiang D. ECM1 regulates the resistance of colorectal cancer to 5-FU treatment by modulating apoptotic cell death and epithelial-mesenchymal transition induction. Front. Pharmacol. 2022 13 1005915 10.3389/fphar.2022.1005915 36408224
    [Google Scholar]
  175. Danesh Pouya F. Rasmi Y. Nemati M. Signaling pathways involved in 5-FU drug resistance in cancer. Cancer Invest. 2022 40 6 516 543 10.1080/07357907.2022.2055050 35320055
    [Google Scholar]
  176. Su Y. Choi H.S. Choi J.H. Kim H.S. Jang Y.S. Seo J.W. 7S,15R-Dihydroxy-16 S,17 S-epoxy-docosapentaenoic acid overcomes chemoresistance of 5-fluorouracil by suppressing the infiltration of tumor-associated macrophages and inhibiting the activation of cancer stem cells in a colorectal cancer xenograft model. Mar. Drugs 2023 21 2 80 10.3390/md21020080 36827121
    [Google Scholar]
  177. Liu Y. Sun Y. Guo Y. Shi X. Chen X. Feng W. Wu L.L. Zhang J. Yu S. Wang Y. Shi Y. An overview: The diversified role of mitochondria in cancer metabolism. Int. J. Biol. Sci. 2023 19 3 897 915 10.7150/ijbs.81609 36778129
    [Google Scholar]
  178. Flores-Romero H. Dadsena S. García-Sáez A.J. Mitochondrial pores at the crossroad between cell death and inflammatory signaling. Mol. Cell 2023 83 6 843 856 10.1016/j.molcel.2023.02.021 36931255
    [Google Scholar]
  179. Li Y. Rasheed M. Liu J. Chen Z. Deng Y. Deciphering the molecular nexus: An in-depth review of mitochondrial pathways and their role in cell death crosstalk. Cells 2024 13 10 863 10.3390/cells13100863 38786088
    [Google Scholar]
  180. Dutta A. Chakraborty A. Ghosh T. Kumar A. 5-Fluorouracil induces apoptosis in nutritional deprived hepatocellular carcinoma through mitochondrial damage. Sci. Rep. 2024 14 1 23387 10.1038/s41598‑024‑73143‑y 39379402
    [Google Scholar]
  181. Kurasaka C. Nishizawa N. Uozumi H. Ogino Y. Sato A. Relationship between anticancer sensitivities and cellular respiration properties in 5‐fluorouracil‐resistant HCT116 human colorectal cancer cells. FEBS Open Bio 2023 13 6 1125 1133 10.1002/2211‑5463.13611 37058332
    [Google Scholar]
  182. Lee H.J. Lim S.H. Lee H. Han J.M. Min D.S. Phospholipase D6 activates Wnt/β-catenin signaling through mitochondrial metabolic reprogramming to promote tumorigenesis in colorectal cancer. Exp. Mol. Med. 2025 57 4 910 924 10.1038/s12276‑025‑01446‑9 40259095
    [Google Scholar]
  183. Dong S. Zhang M. Cheng Z. Zhang X. Liang W. Li S. Li L. Xu Q. Song S. Liu Z. Yang G. Zhao X. Tao Z. Liang S. Wang K. Zhang G. Hu S. Redistribution of defective mitochondria-mediated dihydroorotate dehydrogenase imparts 5-fluorouracil resistance in colorectal cancer. Redox Biol. 2024 73 103207 10.1016/j.redox.2024.103207 38805974
    [Google Scholar]
  184. Zhang X. Jin H. Li D. Liu J. Han J. HADHB mediates 5-fluorouracil sensitivity in colorectal cancer. Discov. Oncol. 2025 16 1 1648 10.1007/s12672‑025‑03503‑1 40875107
    [Google Scholar]
  185. Xu Y. Ni F. Sun D. Peng Y. Zhao Y. Wu X. Li S. Qi X. He X. Li M. Zhou Y. Zhang C. Yan M. Yao C. Zhu S. Yang Y. An B. Yang C. Zhang G. Jiang W. Mi J. Chen X. Wei P. Tian G. Zhang Y. Glucagon enhances chemotherapy efficacy by inhibition of tumor vessels in colorectal cancer. Adv. Sci. 2024 11 6 2307271 10.1002/advs.202307271 38072640
    [Google Scholar]
  186. Gong W. Guo Y. Yuan H. Chai R. Wan Z. Zheng B. Hu X. Chen B. Gao S. Dai Q. Yu P. Tu S. Loss of exosomal miR-200b-3p from hypoxia cancer-associated fibroblasts promotes tumorigenesis and reduces sensitivity to 5-Flourouracil in colorectal cancer via upregulation of ZEB1 and E2F3. Cancer Gene Ther. 2023 30 6 905 916 10.1038/s41417‑023‑00591‑5 36890211
    [Google Scholar]
  187. Kumar A. Singh A.K. Singh H. Thareja S. Kumar P. Regulation of thymidylate synthase: An approach to overcome 5-FU resistance in colorectal cancer. Med. Oncol. 2022 40 1 3 10.1007/s12032‑022‑01864‑z 36308643
    [Google Scholar]
  188. Feng Y. Liao Z. Zhang H. Xie X. You F. Liao X. Wu C. Zhang W. Yang H. Liu Y. Emerging nanomedicines strategies focused on tumor microenvironment against cancer recurrence and metastasis. Chem. Eng. J. 2023 452 139506 10.1016/j.cej.2022.139506
    [Google Scholar]
  189. Tang L. Mei Y. Shen Y. He S. Xiao Q. Yin Y. Xu Y. Shao J. Wang W. Cai Z. Nanoparticle-mediated targeted drug delivery to remodel tumor microenvironment for cancer therapy. Int. J. Nanomedicine 2021 16 5811 5829 10.2147/IJN.S321416 34471353
    [Google Scholar]
  190. Jamialahmadi H. Nazari S.E. TanzadehPanah, H.; Saburi, E.; Asgharzadeh, F.; Khojasteh-Leylakoohi, F.; Alaei, M.; Mirahmadi, M.; Babaei, F.; Asghari, S.Z.; Mansouri, S.; Khalili-Tanha, G.; Maftooh, M.; Fiuji, H.; Hassanian, S.M.; Ferns, G.A.; Khazaei, M.; Avan, A. Targeting transforming growth factor beta (TGF-β) using Pirfenidone, a potential repurposing therapeutic strategy in colorectal cancer. Sci. Rep. 2023 13 1 14357 10.1038/s41598‑023‑41550‑2 37658230
    [Google Scholar]
  191. Pandey P. Lakhanpal S. Mahmood D. Kang H.N. Kim B. Kang S. Choi J. Choi M. Pandey S. Bhat M. Sharma S. Khan F. Park M.N. Kim B. An updated review summarizing the anticancer potential of flavonoids via targeting NF-kB pathway. Front. Pharmacol. 2025 15 1513422 10.3389/fphar.2024.1513422 39834817
    [Google Scholar]
  192. Yaylim İ. Aru M. Farooqi A.A. Hakan M.T. Buttari B. Arese M. Saso L. Regulation of Nrf2/Keap1 signaling pathway in cancer drug resistance by galectin-1: Cellular and molecular implications. Cancer Drug Resist. 2024 7 8 10.20517/cdr.2023.79 38434765
    [Google Scholar]
  193. Zhang X. Ma Y. Ma J. Yang L. Song Q. Wang H. Lv G. Glutathione peroxidase 4 as a therapeutic target for anti-colorectal cancer drug-tolerant persister cells. Front. Oncol. 2022 12 913669 10.3389/fonc.2022.913669 35719967
    [Google Scholar]
  194. Hu Y. Xing Y. Fan G. Xie H. Zhao Q. Liu L. L-arginine combination with 5-fluorouracil inhibit hepatocellular carcinoma cells through suppressing iNOS/NO/AKT-mediated glycolysis. Front. Pharmacol. 2024 15 1391636 10.3389/fphar.2024.1391636 38841361
    [Google Scholar]
  195. Salavati H. Debbaut C. Pullens P. Ceelen W. Interstitial fluid pressure as an emerging biomarker in solid tumors. Biochim. Biophys. Acta Rev. Cancer 2022 1877 5 188792 10.1016/j.bbcan.2022.188792 36084861
    [Google Scholar]
  196. Mai Z. Lin Y. Lin P. Zhao X. Cui L. Modulating extracellular matrix stiffness: A strategic approach to boost cancer immunotherapy. Cell Death Dis. 2024 15 5 307 10.1038/s41419‑024‑06697‑4 38693104
    [Google Scholar]
  197. Desai N. Sahel D. Kubal B. Postwala H. Shah Y. Chavda V.P. Fernandes C. Khatri D.K. Vora L.K. Role of the extracellular matrix in cancer: Insights into tumor progression and therapy. Adv. Ther. 2025 8 2 2400370 10.1002/adtp.202400370
    [Google Scholar]
  198. Torii C. Maishi N. Kawamoto T. Morimoto M. Akiyama K. Yoshioka Y. Minami T. Tsumita T. Alam M.T. Ochiya T. Hida Y. Hida K. miRNA-1246 in extracellular vesicles secreted from metastatic tumor induces drug resistance in tumor endothelial cells. Sci. Rep. 2021 11 1 13502 10.1038/s41598‑021‑92879‑5 34226586
    [Google Scholar]
  199. Ghosh S. Singh R. Vanwinkle Z.M. Guo H. Vemula P.K. Goel A. Haribabu B. Jala V.R. Microbial metabolite restricts 5-fluorouracil-resistant colonic tumor progression by sensitizing drug transporters via regulation of FOXO3-FOXM1 axis. Theranostics 2022 12 12 5574 5595 10.7150/thno.70754 35910798
    [Google Scholar]
  200. Yue Y. Zhang Q. Wang X. Sun Z. STAT3 regulates 5‐Fu resistance in human colorectal cancer cells by promoting Mcl‐1-dependent cytoprotective autophagy. Cancer Sci. 2023 114 6 2293 2305 10.1111/cas.15761 36788743
    [Google Scholar]
  201. Patel D. Sethi N. Patel P. Shah S. Patel K. Exploring the potential of P-glycoprotein inhibitors in the targeted delivery of anti-cancer drugs: A comprehensive review. Eur. J. Pharm. Biopharm. 2024 198 114267 10.1016/j.ejpb.2024.114267 38514020
    [Google Scholar]
  202. Umemoto T. Kobayashi Y. Suzuki M. Sanada Y. Yamamoto T. Cloning and pharmacological characterization of a novel gene encoding human nucleoside transporter 1 (hNT1) from a human breast cancer cDNA library. Life Sci. 2009 84 1-2 45 51 10.1016/j.lfs.2008.10.015 19032958
    [Google Scholar]
  203. Awad N.S. Salkho N.M. Abuwatfa W.H. Paul V. AlSawaftah N.M. Husseini G.A. Tumor vasculature vs tumor cell targeting: Understanding the latest trends in using functional nanoparticles for cancer treatment. OpenNano 2023 11 100136 10.1016/j.onano.2023.100136
    [Google Scholar]
  204. Han J.H. Kim M. Kim H.J. Jang S.B. Bae S.J. Lee I.K. Ryu D. Ha K.T. Targeting lactate dehydrogenase A with catechin resensitizes SNU620/5FU gastric cancer cells to 5-fluorouracil. Int. J. Mol. Sci. 2021 22 10 5406 10.3390/ijms22105406 34065602
    [Google Scholar]
  205. Mironiuk-Puchalska E. Karatsai O. Żuchowska A. Wróblewski W. Borys F. Lehka L. Rędowicz M.J. Koszytkowska-Stawińska M. Development of 5-fluorouracil-dichloroacetate mutual prodrugs as anticancer agents. Bioorg. Chem. 2023 140 106784 10.1016/j.bioorg.2023.106784 37639758
    [Google Scholar]
  206. Zhang T. He Z. Qi X. Zhang Y. Liu Y. Jin L. Wang T. 5-Fluorouracil resistant CRC cells derived exosomes promote cancer-associated fibroblasts secreting more CXCL12. J. Cancer 2024 15 11 3441 3451 10.7150/jca.95248 38817851
    [Google Scholar]
  207. Qiao X.X. Shi H.B. Xiao L. Serum exosomal hsa-circ-0004771 modulates the resistance of colorectal cancer to 5-fluorouracil via regulating miR-653/ZEB2 signaling pathway. Cancer Cell Int. 2023 23 1 243 10.1186/s12935‑023‑03072‑9 37845688
    [Google Scholar]
  208. Ezike T.C. Okpala U.S. Onoja U.L. Nwike C.P. Ezeako E.C. Okpara O.J. Okoroafor C.C. Eze S.C. Kalu O.L. Odoh E.C. Nwadike U.G. Ogbodo J.O. Umeh B.U. Ossai E.C. Nwanguma B.C. Advances in drug delivery systems, challenges and future directions. Heliyon 2023 9 6 e17488 10.1016/j.heliyon.2023.e17488 37416680
    [Google Scholar]
  209. Chen Q. Yang Z. Liu H. Man J. Oladejo A.O. Ibrahim S. Wang S. Hao B. Novel drug delivery systems: An important direction for drug innovation research and development. Pharmaceutics 2024 16 5 674 10.3390/pharmaceutics16050674 38794336
    [Google Scholar]
  210. Shao X. Zhao X. Wang B. Fan J. Wang J. An H. Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy. Theranostics 2025 15 5 1689 1714 10.7150/thno.103636 39897552
    [Google Scholar]
  211. Entezar-Almahdi E. Mohammadi-Samani S. Tayebi L. Farjadian F. Recent advances in designing 5-fluorouracil delivery systems: A stepping stone in the safe treatment of colorectal cancer. Int. J. Nanomedicine 2020 15 5445 5458 10.2147/IJN.S257700 32801699
    [Google Scholar]
  212. Aycan D. Gül İ. Yorulmaz V. Alemdar N. Gelatin microsphere-alginate hydrogel combined system for sustained and gastric targeted delivery of 5-fluorouracil. Int. J. Biol. Macromol. 2024 255 128022 10.1016/j.ijbiomac.2023.128022 37972837
    [Google Scholar]
  213. Zhang Z. Fang C. Ke J. Li Y. Duan M. Ren J. Wang C. Microneedle drug delivery system based on hyaluronic acid for improving therapeutic efficiency of hypertrophic scars. Int. J. Biol. Macromol. 2025 297 139790 10.1016/j.ijbiomac.2025.139790 39805460
    [Google Scholar]
  214. Hani U. Mahammed N. Reshma T. Talath S. Wali A.F. Aljasser A. Al Fatease A. Alamri A.H. Khan S. Enhanced colon-targeted drug delivery through development of 5-fluorouracil-loaded cross-linked mastic gum nanoparticles. Sci. Rep. 2025 15 1 18355 10.1038/s41598‑025‑03533‑3 40419601
    [Google Scholar]
  215. Valencia-Lazcano A.A. Hassan D. Pourmadadi M. shamsabadipour, A.; Behzadmehr, R.; Rahdar, A.; Medina, D.I.; Díez-Pascual, A.M. 5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy. Eur. J. Med. Chem. 2023 246 114995 10.1016/j.ejmech.2022.114995 36493619
    [Google Scholar]
  216. Lei F. Zeng F. Yu X. Deng Y. Zhang Z. Xu M. Ding N. Tian J. Li C. Oral hydrogel nanoemulsion co-delivery system treats inflammatory bowel disease via anti-inflammatory and promoting intestinal mucosa repair. J. Nanobiotechnology 2023 21 1 275 10.1186/s12951‑023‑02045‑4 37596598
    [Google Scholar]
  217. Zhang Y. Wang Y. Lu Y. Quan H. Wang Y. Song S. Guo H. Advanced oral drug delivery systems for gastrointestinal targeted delivery: The design principles and foundations. J. Nanobiotechnology 2025 23 1 400 10.1186/s12951‑025‑03479‑8 40448152
    [Google Scholar]
  218. Mao H.Y. Xu J. Hong S. Piao J.S. Piao M.G. Oral site-specific drug delivery system: Functionalized modified hyaluronic acid 5-fluorouracil microspheres for colon cancer. J. Pharm. Innov. 2025 20 3 88 10.1007/s12247‑025‑09967‑6
    [Google Scholar]
  219. Bereyhi M. Zare-Dorabei R. Safarifard V. A biocompatible NMOF-based drug delivery system designed for the sustained and controlled release via pH-responsive poorly soluble drug 5-fluorouracil. Langmuir 2025 41 10 6544 6552 10.1021/acs.langmuir.4c03953 40056115
    [Google Scholar]
  220. Zhou J. Jia D. Jin L. He W. Zhang Z. Zhang Z. Wu T. Häfeli U.O. Liu X. Han X. Wei S. Gong T. An injectable hydrogel for synergistic therapy in colorectal cancer by targeting glutathione. Cell Rep. Phys. Sci. 2025 6 2 102399 10.1016/j.xcrp.2024.102399
    [Google Scholar]
  221. Ema N.J. Hossain S.M.R. Shahriar S. Islam M.R. Chowdhury J.A. Development of resistant starch-pectin microsphere for improving oral colon-specific drug delivery of 5-fluorouracil. Bangladesh Pharm. J. 2023 26 1 36 44 10.3329/bpj.v26i1.64216
    [Google Scholar]
  222. Kaur P. Ghosh S. Bhowmick A. Gadhave K. Datta S. Ghosh A. Garg N. Mahajan R.L. Basu B. Choudhury D. Bacterioboat—A novel tool to increase the half-life period of the orally administered drug. Sci. Adv. 2022 8 10 eabh1419 10.1126/sciadv.abh1419 35275724
    [Google Scholar]
  223. Sun X. Shan X. Zhu B. Cai Y. He Z. Zhou L. Yin L. Liu Y. Liu K. Zhang T. Yang N. Li Y. Lang T. 5‐fluorouracil loaded prebiotic-probiotic liposomes modulating gut microbiota for improving colorectal cancer chemotherapy. Adv. Healthc. Mater. 2025 14 4 2403587 10.1002/adhm.202403587 39676353
    [Google Scholar]
  224. Li X. Zhao F. Rong W. Li D. Xie H. A mucoadhesive magnetic millimeter-scale robot with two motion modes for drug delivery to the colon. Appl. Mater. Today 2023 35 101941 10.1016/j.apmt.2023.101941
    [Google Scholar]
  225. Crasta A. Painginkar T. Sreedevi A. Pawar S.D. Badamane Sathyanarayana M. Vasantharaju S.G. Osmani R.A.M. Ravi G. Transdermal drug delivery system: A comprehensive review of innovative strategies, applications, and regulatory perspectives. OpenNano 2025 24 100245 10.1016/j.onano.2025.100245
    [Google Scholar]
  226. Vaseem R.S. D’cruz A. Shetty S. Hafsa H. Vardhan A. R, S.S.; Marques, S.M.; Kumar, L.; Verma, R. Transdermal drug delivery systems: A focused review of the physical methods of permeation enhancement. Adv. Pharm. Bull. 2024 14 1 67 85 10.34172/apb.2024.018 38585458
    [Google Scholar]
  227. Kumar S. Shukla R. Advancements in microneedle technology: Current status and next-generation innovations. J. Microencapsul. 2024 41 8 782 803 10.1080/02652048.2024.2418613 39475226
    [Google Scholar]
  228. Shao J. Li X. Li Y. Lin J. Huang P. Self‐heating multistage microneedle patch for topical therapy of skin cancer. Adv. Mater. 2024 36 15 2308217 10.1002/adma.202308217 38198412
    [Google Scholar]
  229. Suriyaamporn P. Pornpitchanarong C. Charoenying T. Dechsri K. Ngawhirunpat T. Opanasopit P. Pamornpathomkul B. Artificial intelligence-driven hydrogel microneedle patches integrating 5-fluorouracil inclusion complex-loaded flexible pegylated liposomes for enhanced non-melanoma skin cancer treatment. Int. J. Pharm. 2025 669 125072 10.1016/j.ijpharm.2024.125072 39675535
    [Google Scholar]
  230. Zhang L. Lv J. Yin Y. Ling G. Zhang P. Rapidly separable microneedle patch for the controlled and sustained release of 5-fluorouracil. Int. J. Pharm. 2023 635 122730 10.1016/j.ijpharm.2023.122730 36796660
    [Google Scholar]
  231. Ma H. Li Y. Yao Q. Qin R. Wang Y. Wu W. Luo H. Zhao Q. Ye H. Wu K. Self-assembled arginine-based eutectogel microneedles as novel transdermal delivery system for pigmentation treatment. Giant 2025 23 100357 10.1016/j.giant.2025.100357
    [Google Scholar]
  232. Pansuriya R. Patel T. Kumar S. Aswal V.K. Raje N. Hoskins C. Kailasa S.K. Malek N.I. Multifunctional ionic hydrogel-based transdermal delivery of 5-fluorouracil for the breast cancer treatment. ACS Appl. Bio Mater. 2024 7 5 3110 3123 10.1021/acsabm.4c00152 38620030
    [Google Scholar]
  233. Mehan N. Saini V. Manish K. Goyal M. Devi S. Pottathil S. Jacob S. Nair A.B. Formulation, characterization and in vivo evaluation of 5-fluorouracil-loaded polymeric micelles for non-melanoma skin cancer. Indian J. Pharm. Educ. Res. 2025 59 2 602 616 10.5530/ijper.20251736
    [Google Scholar]
  234. Pachauri A. Chitme H. Visht S. Chidrawar V. Mohammed N. Abdel-Wahab B.A. Khateeb M.M. Habeeb M.S. Orabi M.A.A. Bakir M.B. Permeability-enhanced liposomal emulgel formulation of 5-fluorouracil for the treatment of skin cancer. Gels 2023 9 3 209 10.3390/gels9030209 36975657
    [Google Scholar]
  235. Liao A.H. Lee Y.A. Lin D.L. Chuang H.C. Wang J.K. Chang C.E. Li H.T. Wu T.Y. Shih C.P. Wang C.H. Chu Y.H. Treatment efficacy of low-dose 5-fluorouracil with ultrasound in mediating 5-fluorouracil-loaded microbubble cavitation in head and neck cancer. Drug Deliv. 2023 30 1 1 13 10.1080/10717544.2022.2154410 36579479
    [Google Scholar]
  236. Javadi P. Derakhshan M.A. Heidari R. Ashrafi H. Azarpira N. Shahbazi M.A. Azadi A. A thermoresponsive chitosan-based in situ gel formulation incorporated with 5-FU loaded nanoerythrosomes for fibrosarcoma local chemotherapy. Int. J. Biol. Macromol. 2024 278 Pt 4 134781 10.1016/j.ijbiomac.2024.134781 39151860
    [Google Scholar]
  237. Shirvalilou S. Khoee S. Khoei S. Karimi M.R. Sadri E. Shirvaliloo M. Targeted magnetochemotherapy modified by 5-Fu-loaded thermally on/off switching nanoheaters for the eradication of CT26 murine colon cancer by inducing apoptotic and autophagic cell death. Cancer Nanotechnol. 2023 14 1 11 10.1186/s12645‑023‑00164‑z
    [Google Scholar]
  238. Zeng D. Wu N. Xie L. Xia X. Kang Y. An experimental study of a spring-loaded needle-free injector: Influence of the ejection volume and injector orifice diameter. J. Mech. Sci. Technol. 2019 33 11 5581 5588 10.1007/s12206‑019‑1051‑1
    [Google Scholar]
  239. Sutedja E.K. Sundani A. Ruchiatan K. Sutedja E. Spring-powered needle-free injection of triamcinolone acetonide and 5-fluorouracil for keloid treatment. Clin. Cosmet. Investig. Dermatol. 2023 16 1659 1665 10.2147/CCID.S415789 37396709
    [Google Scholar]
  240. Komarova E.G. Senkina E.I. Lozhkomoev A.S. Kazantseva E.A. Prosolov K.A. Kazantsev S.O. Akimova E.B. Tolkacheva T.V. Khimich M.A. Sharkeev Y.P. Controlled anticancer 5-Fluorouracil release from functionalized 5-FU/PLGA/CaP coating on titanium implants: Characterization, in vitro drug delivery and cytotoxicity. Mater. Today Commun. 2024 39 109332 10.1016/j.mtcomm.2024.109332
    [Google Scholar]
  241. Fernandes N.B. Velagacherla V. Spandana K.J. N, B.; Mehta, C.H.; Gadag, S.; Sabhahit, J.N.; Nayak, U.Y. Co-delivery of lapatinib and 5-fluorouracil transfersomes using transpapillary iontophoresis for breast cancer therapy. Int. J. Pharm. 2024 650 123686 10.1016/j.ijpharm.2023.123686 38070658
    [Google Scholar]
  242. Ramzan M. Khan T. Siddique M.U.M. Shahid M. Biocompatible cationic 5-fluorouracil loaded elastic liposomes for ocular delivery: In vitro, ex vivo, and in vivo evaluation. J. Drug Deliv. Sci. Technol. 2024 101 106278 10.1016/j.jddst.2024.106278
    [Google Scholar]
  243. Chen D. Wu Z. Xia C. Yang H. Ding W. He Q. A sustained H2/fluorouracil‐releasing suppository for high‐efficacy and low‐toxicity hydrogenochemotherapy of colon cancer. Adv. Healthc. Mater. 2025 14 7 2404054 10.1002/adhm.202404054 39838815
    [Google Scholar]
  244. Deng X. Gould M.L. Katare R.G. Ali M.A. Melt-extruded biocompatible surgical sutures loaded with microspheres designed for wound healing. Biomed. Mater. 2024 19 5 055007 10.1088/1748‑605X/ad5baa 38917838
    [Google Scholar]
  245. Alsaedi M.K. Lone O. Nejad H.R. Das R. Owyeung R.E. Del-Rio-Ruiz R. Sonkusale S. Soft injectable sutures for dose‐controlled and continuous drug delivery. Macromol. Biosci. 2024 24 3 2300365 10.1002/mabi.202300365 37840462
    [Google Scholar]
  246. Zhao B. Li X. Kong Y. Wang W. Wen T. Zhang Y. Deng Z. Chen Y. Zheng X. Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy. Front. Bioeng. Biotechnol. 2022 10 1010724 10.3389/fbioe.2022.1010724 36159668
    [Google Scholar]
  247. Sandbhor P. Palkar P. Bhat S. John G. Goda J.S. Nanomedicine as a multimodal therapeutic paradigm against cancer: On the way forward in advancing precision therapy. Nanoscale 2024 16 13 6330 6364 10.1039/D3NR06131K 38470224
    [Google Scholar]
  248. Marok F.Z. Wojtyniak J.G. Selzer D. Dallmann R. Swen J.J. Guchelaar H.J. Schwab M. Lehr T. Personalized chronomodulated 5‐fluorouracil treatment: A physiologically‐based pharmacokinetic precision dosing approach for optimizing cancer therapy. Clin. Pharmacol. Ther. 2024 115 6 1282 1292 10.1002/cpt.3181 38264789
    [Google Scholar]
  249. Zhao S. Yu N. Han H. Guo S. Murthy N. Advances in acid-degradable and enzyme-cleavable linkers for drug delivery. Curr. Opin. Chem. Biol. 2025 84 102552 10.1016/j.cbpa.2024.102552 39642424
    [Google Scholar]
  250. Shao S. Stocker M.W. Zarrella S. Korter T.M. Singh A. Healy A.M. In situ cocrystallization via spray drying with polymer as a strategy to prevent cocrystal dissociation. Mol. Pharm. 2023 20 9 4770 4785 10.1021/acs.molpharmaceut.3c00564 37595572
    [Google Scholar]
  251. Li Z. Shen H. Cai W. Xu Q. Xia W. Ning K. Liu E. Huang Y. Colon-targeted pellets encapsulating patchouli oil cocrystal for inflammatory bowel disease treatment. Chin. Chem. Lett. 2025 111292 10.1016/j.cclet.2025.111292
    [Google Scholar]
  252. Das S. Saha M. Mahata L.C. China A. Chatterjee N. Das Saha K. Quercetin and 5-Fu loaded chitosan nanoparticles trigger cell-cycle arrest and induce apoptosis in HCT116 cells via modulation of the p53/p21 axis. ACS Omega 2023 8 40 36893 36905 10.1021/acsomega.3c03933 37841142
    [Google Scholar]
  253. Cahn D. Stern A. Buckenmeyer M. Wolf M. Duncan G.A. Extracellular matrix limits nanoparticle diffusion and cellular uptake in a tissue-specific manner. ACS Nano 2024 18 46 32045 32055 10.1021/acsnano.4c10381 39499215
    [Google Scholar]
  254. Paone L.S. Jin Y. Bouyer J. Fischer I. Galie P.A. Development of a multifunctional, injectable biomaterial using hyaluronan as a bioactive nanocarrier. Biomaterials 2026 324 123505 10.1016/j.biomaterials.2025.123505 40554217
    [Google Scholar]
  255. Yang Y. Li H. Xie H. Hao J. Carrier-free, pure nanodrugs based on dasatinib and 5-Fluorouracil show aggregation-induced emission and enhanced antitumor efficacy. J. Drug Deliv. Sci. Technol. 2023 90 105142 10.1016/j.jddst.2023.105142
    [Google Scholar]
/content/journals/ctmc/10.2174/0115680266429032251207122337
Loading
Recent Advances and Future Directions in 5-Fluorouracil Drug Delivery: A Comprehensive Review
Bentham Science Publishers ; https://doi.org/10.2174/0115680266429032251207122337
/content/journals/ctmc/10.2174/0115680266429032251207122337
/content/journals/ctmc/10.2174/0115680266429032251207122337
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Drug delivery devices ; 5-FU ; Drug modification techniques ; Drug delivery technologies ; Microenvironment

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test